Statistics, uncertainty and the physician

Jay Brophy MD PhD

Departments of Medicine, Epidemiology and Biostatistics, McGill University

2025-01-07

Conflicts of interest


No conflicts of interest
To the best of my knowledge I’m equally disliked, or at best deemed irrelevant, by all drug and device companies


AI generated image

Objectives


Review of some probability concepts

Review of statistical inference concepts

Realization of their practical applications

Are statistics (math) important for MDs?

2012 Harvard study suggests the answer is YES

What are the benefits of “good” stats knowledge?


For producers of clinical research helps

  • collection and analysis of the data

  • recognition & acknowledgement of uncertainty

  • interpretation & presentation of the results

For consumers of clinical research helps

  • their appreciation & understanding of new knowledge

  • formation of reasonable conclusions

  • good decision making

Metascience - study of science itself

Hypothetico-deductive model of the scientific method

Metascience

Where this talk concentrates

Metascience

Plenty of other places to go wrong besides “stats”

Statistical inference


Statistical inference: learning from a sample about the underlying population (without it we’re left simply with our data)

Samples data are “noisy”, need to account for uncertainty

Inferences require referral to common statistical distributions (or else simulations)

Statistical models alone are insufficient for causality, remember
\[association \ne causation\]

Basic Probability Distributions

Understanding probability requires understanding what probability distributions could have generated the observed data

Common probability distributions

Normal and t distributions

Normal distributions are common due to CLT, many random variables that are the sum of independent processes, such as measurement errors, are often close to normal.

Mathematically the normal distribution is expressed as \[f(x) = \frac{1}{\sqrt{2 \pi \sigma^2}} e^{-\frac{(x-\mu)^2}{2 \sigma^2}}\]

where \({\mu}\) is the mean or expectation of the distribution (and also its median and mode)

\({\sigma^{2}}\) is the variance and \({\sigma }\) is the standard deviation  

Student’s t “fatter” tails as f(df)

Graphically, probability density functions (pdf)

Normal and t distributions

Cumulative distribution function (CDF) - is the integral of the PDF (i.e. the area under the curve) and represents the probability that a random variable will take a value less than or equal to a specific point or btw 2 points. 

Uniform distribution

The uniform distribution assumes that all continuous outcomes between boundaries have an equal probability of occurring.

Of interest in Bayesian statistics as a prior non-informative distribution which allows the observed data to completely dominate the final (posterior) distribution.

Mathematically this is expressed as
\[PDF(x) = \frac{1}{b-a} \,\, for \, a \le x \le b\] PDF = probability density funcion

Graphically

mean(x) = \(\frac{1}{2(b-a)}\)
var(x) = \(\frac{(b-a)^2}{12}\)

Binomial Distribution

Discrete data, binomial distribution -> 
# successes in a fixed number of independent Bernoulli trials (0,1), each with same P(success), like coin flips.

Probability mass function (pmf)   \[P(X = k) = {n \choose k} * p^k * (1 - p)^{n-k}\]P(X=k) = P(k successes in n trials)  
\({n \choose k}\) # ways choose k from n  
p = P (success in each trial)  
1-p = P (failure in each trial)  


Models any binary independent outcomes with many applications in medicine 

Graphically

Poisson Distribution

Discrete probability distribution for random, independent, and rare # events in a time interval with constant rate, \(\lambda\)   Probability mass function (pmf)   \[P(X = k) = \frac{\lambda^k * e^{-\lambda}}{k!}\] 
P(X=k) P(k events in a given time period)  
\(\lambda\) is the expectation of the # events over the same time period  
variance = mean (E(Y)) 

Graphically


Poisson P(k events with \(\lambda = \textit{np}) \approx\) Binomial P(k events in n trials)  

If n -> \(\infty\) & p (any trial success) -> 0

Probability

Statistical inferences depends on Probability, branch of mathematics of how likely events occur 

Contrasting views of probability

Null hypothesis significance testing (frequentist) inference: views probability as a long run frequency.  

Answers questions like “What should I decide given my data, controlling the long run proportion of mistakes I make at a tolerable level.”

Bayesian inference: views probability as a calculus of beliefs.  

Answers questions like “Given my prior beliefs and the objective information from the data, what should I now believe?”

Frequentist vs Bayesian (summary)

Frequentist Bayesian
Probability is “long-run frequency” Probability is “degree of certainty”
\(Pr(X \mid \theta)\) is a sampling distribution
(function of variable \(X\) with fixed \(\theta\))
\(Pr(X \mid \theta)\) is a likelihood
(function of fixed \(X\) with variable \(\theta\))
No prior Prior
P-values (NHST) Full posterior probability model available for summary/decisions
Confidence intervals Credible intervals
Violates the “likelihood principle”1:
 Sampling intention matters
 Corrections for multiple testing
 Adjustment for planned/post hoc testing
Respects the “likelihood principle”:
 Sampling intention is irrelevant
 No corrections for multiple testing
 No adjustment for planned/post hoc testing
Objective? Subjective?

How well do we understand probability?

A case study

A 2024 publication “One-Year Outcomes of Transseptal Mitral Valve in Valve in Intermediate Surgical Risk Patients” in Circulation: Cardiovascular Interventions based on 50 MVIV patients, concluded in symptomatic patients with a failing mitral bioprosthesis that

“Mitral valve-in-valve with a balloon-expandable valve via transseptal approach in intermediate-risk patients was associated with improved symptoms and quality of life, adequate transcatheter valve performance, & no mortality or stroke at 1-year follow-up.”

According to the authors, expected 1 year STS mortality was 4%  
I wondered what is the probability of seeing 0 deaths if MVIV had same redo mortality 

I also wondered what would be my colleagues’ probability estimates.

Quiz 1 questions

Q1. What P(observing 0 deaths | MVIV mortality = expected 4% redo mortality)

  1. <1%
  2. 1 - 4.9%
  3. 5 -9.9%
  4. 10 - 14.9%
  5. > 15%

Q2. What P(observing 0 deaths | MVIV mortality = 40% higher expected redo mortality)

  1. <1%
  2. 1 - 4.9%
  3. 5 -9.9%
  4. 10 - 14.9%
  5. > 15%

Q3. Given only this study, what is P(MVIV is as safe or safer than a redo)?

  1. < 25 %
  2. 25 - 50%
  3. 51 - 75%
  4. 76 - 95%
  5. > 95%

Quiz 1 Results

15 (42%, n= 36) MUHC cardiology staff, 4 (18%, n = 22) fellows, 4 GIM staff replied
Q1. P(0 deaths | true death rate 4%)?
Q2. P(0 deaths | true death rate 5.6%)? (i.e. 40% increase)?

Lots of variability, n’est-ce pas?

Quiz 1 Q1 Discussion

Discrete data -> Poisson (counts) or a binomial (independent Bernoulli trials) distribution  
Calculations by hand via above equations or any software with distribution functions.

Q1. P(0 deaths | true death rate 4%)?
With one line of code in R
db <- 100*dbinom(c(0:6),50, .04)

Assuming a binomial distribution with an event (death) probability of 4%, the probability for 0, 1, 2, 3, 4, 5, 6 events is 13%, 27.1%, 27.6%, 18.4%, 9%, 3.5%, respectively.

Assuming a Poisson distribution with an event (death) rate of 2 (# deaths in 50 pts in 1 year with 4% annual mortality)  
Again from a single line of R code dp <- 100*dpois(c(0:6),2) 
P(0, 1, 2, 3, 4, 5, 6 events) is 13.5%, 27.1%, 27.1%, 18%, 9%, 3.6%, respectively.  


Therefore the answer to Q1 is 10 - 14.9%

Quiz 1 Q1 Discussion

Visualiztions emphasizing the similarity between the Poisson and Binomial distributions.

Therefore the answer to Q1 is 10 - 14.9%

Quiz 1 Q2 Discussion


Q2. P(0 deaths | true death rate 5.6%)?   (i.e. 40% increase)?

Again with a single line of R code
dp1 <- 100*dpois(c(0:6),2.8)


Assuming a P(2.8) (rate = # deaths in 50 individual in 1 year with 5.6% expected mortality = 50*.056), the probability for 0, 1, 2, 3, 4, 5, 6 events is 6.1%, 17%, 23.8%, 22.2%, 15.6%, 8.7%, respectively.

Assuming a binomial, the probability for 0, 1, 2, 3, 4, 5, 6 events is 5.6%, 16.6%, 24.2%, 22.9%, 16%, 8.7%, respectively.

Graphically

If expected(death rate) is higher, the curves shift right   P(observing 0 deaths) will fall, so

The answer to Q2 is 5 - 9.9%

Quiz 1 Q3 Results

Q3. P(MVIV as safer or safer than redo)?
IOW P(MVIV mortality <4%)

Again lots of variability, n’est-ce pas?

Quiz 1 Q3 Answer & Discussion

Q3. P(MVIV as safer or safer than redo)

Ideally want RCT & hope that subjects in each arm are exchangeable.   Here, no RCT but assuming the STS model is accurate can do a simulation with 50 observed MVIV results and 50 counterfactual simulated subjects receiving a redo operation with 4% mortality.  Perform logistic regression (e.g.success | trials(total) ~ Tx, family = binomial)

 Family: binomial 
  Links: mu = identity 
Formula: success | trials(total) ~ Tx 
   Data: dat1 (Number of observations: 2) 
  Draws: 4 chains, each with iter = 10000; warmup = 5000; thin = 1;
         total post-warmup draws = 20000

Regression Coefficients:
          Estimate Est.Error l-95% CI u-95% CI Rhat Bulk_ESS Tail_ESS
Intercept     0.98      0.02     0.93     1.00 1.00     1229     2480
Txredo       -0.04      0.04    -0.13     0.03 1.01      703      521

Draws were sampled using sample(hmc). For each parameter, Bulk_ESS
and Tail_ESS are effective sample size measures, and Rhat is the potential
scale reduction factor on split chains (at convergence, Rhat = 1).

As expected, mean mortality difference (MVIV - redo) is - 4% but this Bayesian model also now gives us a measure of the associated uncertainty with 95% CrI -13% to 3%

Quiz 1 Q3 Discussion

The probability density for this mortality difference is plotted here

This shows a 12% probability (blue AUC) that MVIV patients in this study would have a worse outcome with a surgical redo, provided their counterfactual mortality has been well predicted with the STS model. IOW, P(MVIV is as safe or safer than a redo) = 88.3% (grey AUC).

Therefore the answer to Q3 is 76-95%

Quiz 1 How did we do?

Q1, Only 26% (6/23) correctly estimated was a 10-14.9% probability of observing 0 deaths, if true rate was 4%. 7 of 23 (30%) estimated this probability as < 5%.

Q2,74% (17/23) respondents correctly reasoned that if the true underlying mortality increased, less likely to observe 0 deaths but a 26% (6/23) didn’t.

Q3 Only 9% (2/23) responses correctly estimated P(MVIV as safe or safer than a redo) = 76-95%. 15 of 23 (65%) of respondents estimated this probability at being under 50%.

Q1-3, No one gave all 3 correct answers

Limitations
i) small sample size of respondents
ii) unknown if respondents have better, worse or same quantitative skills as the non-respondents.

Notwithstanding limitations, suggests additional quantitative probability training may be helpful.

(In)famous P value

Definition
𝑝-value is the probability under the null hypothesis and an assumed data-generating model, that an appropriate test statistic would be as or more extreme than what was observed.
\(P(data | H_o, \ model\))

Quiz 2

Consider an encouraging experiment with true effect = 2 standard errors from zero (N(2,1) 
Imagine a simulation where the same experiment is repeated 10 times. 
What do you think is the range of the 10 p values? 
1. 0.02 to 0.05
2. 0.002 to 0.05
3. 0.0002 to 0.05
4. 0.0002 to 0.5

Again one line of R code
set.seed(123) # for reproducibility
p_value <- 2*(1 - pnorm(abs(rnorm(10, 2, 1)))) # 10 random draws from N(2,1) 
print(p_value) # Print the 10 random draws  
0.1500, 0.0767, 0.0003, 0.0384, 0.033,
0.0002, 0.0138, 0.4623, 0.1891, 0.1201

Quiz 2 Answer

Quiz 2 Answer

How can this be?

Even though we KNOW the effect = 2, about 1/2 the time p > 0.05 meaning we should accept H\(_o\) of no effect!

Quiz 2 What says ChatGPT4?

“If we assume minor variations around the 2 standard errors effect size, p-values might typically range from just below 0.0456 to slightly above it. For example, if some experiments measure the effect size at slightly less than 2 or slightly more than 2 standard errors, the p-values could range approximately between 0.04 and 0.05.”


 

THIS IS WRONG.

Quiz 2 Q1 ChatGPT4 after shown simulation?

ChatGPT4: “Your simulation highlighted the variability that can occur in experimental results due to random sampling, which indeed can lead to a much broader range of p-values. It demonstrates that even if the true effect size is relatively large, the exact p-values obtained in any given experiment can vary widely.”

Me: “If you ask the same question tomorrow or in the future, will you update your response accordingly?”

ChatGPT4: “My response will certainly take into account this discussion and the insights from your simulation.”


IT ABSOLUTELY DIDN’T AS WHEN ASKED THE SAME QUESTION 1 WEEK LATER IT GAVE THE SAME INCORRECT RESPONSE.

Quiz 2 Discussion

The larger points are:

  1. The p-value is a statement relative to the null hypothesis of no effect, doesn’t have much of an interpretation relative to a real, nonzero effect.

  2. The p-value is a weird nonlinear transformation of the z-score with nonintuitive behavior & is super-noisy

  3. Even ChatGPT4 doesn’t realize how nosiy p values are!

  4. You can learn a lot from simulations.


    Andrew Gelman’s Blog

Bayesian Inference

Bayes’ Theorem -> probability statements about hypotheses, model parameters or anything else that has associated uncertainty

Advantages
treats unknown parameters as random variables -> direct and meaningful answers (estimates)

allows integration of all available information -> mirrors sequential human learning with constant updating

allows consideration of complex questions / models where all sources of uncertainty can be simultaneously and coherently considered

Disadvantages
subjectivity (?) & problem of induction (Hume / Popper - difficulty generalizing about future)

Probabilities with 2 arm studies

A 2023 RCT in the NEJM concluded “In patients with refractory out-of-hospital cardiac arrest, extracorporeal CPR and conventional CPR had similar effects on survival with a favorable neurologic outcome

Are the results truly similar?
What do MUHC cardiologists think?

Quiz 3 Q1

MUHC cardiologists (51% response rate, 18 of 35) gave their probabilities that eCPR was superior to cCPR

Only 2 of the cardiologist gave >50% probability of eCPR being superior

Quiz 3 Q2

The respondents were next provided with 2 previous trials of e-CRP with these results

name n_ecrp survival_ecrp n_ctl survival_ctl
ARREST 15 6 15 1
PRAGUE 124 38 132 24

Both trials showed improved 30 day survival with eCPR.
The respondents were then asked to update their previous probabilities that eCRP is better than cCRP

Quiz 3 Q2

Slight overall shift in >50% from 2 to 5 respondents but still collectively 13/18 < 50%

Quiz 3 Q2

How did MUHC cardiologists update their beliefs with additional evidence?

Observations: i) Original authors claimed “similarity” but actually greater 50% probability of eCPR superiority based on their data and 76-95% with prior data ii) 16/18 MUHC cardiologists increased their probability estimate with the new data but iii) their original low estimate has a persistent grounding effect on revised estimates

Conclusions

Gut1 (heuristic) probability estimates are widely variable & often very far from probabilistic quantified effects

Statistical literacy depends on appreciating and understanding the underlying probability distributions.

Statistical literacy improves diagnostic and therapeutic decision-making.

Undergraduate and graduate medical education should consider improving their quantitative training.




Acknowledgements



My PhD supervisor, (emeritus) Professor Lawrence Joseph, arguably Canada’s first Bayesian biostatistician


Fonds de Recherche du Québec (Santé) whose salary support (1999 - 2023) allowed me to pursue these statistical musings.

References

  1. Brophy JM. Key Issues in the Statistical Interpretation of Randomized Clinical Trials. Canadian Journal of Cardiology. 2021;37(9):1312-1321

  2. Brophy JM. Bayesian Analyses of Cardiovascular Trials-Bringing Added Value to the Table. Can J Cardiol. 2021;37(9):1415-1427

  3. Heuts S et. al. Bayesian Analytical Methods in Cardiovascular Clinical Trials (A hands-on tutorial). Can J Cardiol online

Statistical code is available online for the above references

Slides available here

Thank you


Barney (2011-) friend, running partner, and favorite muse